Bionor Immuno AS focuses on the development of therapeutic and preventative vaccines targeting
infectious diseases and cancer. Highly specific peptide design and intradermal delivery allow for
optimum presentation of the peptides to the immune system. The immune responses generated
are specific for the target pathogen and aim to induce and/or enhance sustainable immune
responses to viral antigens. Bionor Immuno is developing peptide vaccine antigens that aim to
stimulate cell-mediated immunity (to remove infected cells) and /or induce
non-neutralizing antibodies (humoral immunity) that can modulate disease progression.